Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 5/20 | 0.54 |
| ▸ | HTT | P42858 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 4/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | CETP | P11597 | 1/20 | 0.47 |
| ▸ | PDK1 | Q15118 | 3/20 | 0.46 |
| ▸ | PDK2 | Q15119 | 3/20 | 0.46 |
| ▸ | PDK3 | Q15120 | 3/20 | 0.46 |
| ▸ | PDK4 | Q16654 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | METAP2 | P50579 | 1/20 | 0.45 |
| ▸ | MMP1 | P03956 | 1/20 | 0.45 |
| ▸ | MMP2 | P08253 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8023112 | 0.88 | CETP (0.53) | HTTNPC1CETPPDK1PDK2 | |
| SCHEMBL8243174 | 0.86 | CETP (0.62) | GAAHTTLMNAMAPTNPC1 | |
| SCHEMBL27997031 | 0.84 | GAA (0.50) | GAAHTTLMNAMAPTNPC1 | |
| SCHEMBL19280535 | 0.81 | PDK1 (0.68) | GAAHTTLMNAMAPTNPC1 | |
| SCHEMBL10027976 | 0.80 | LMNA (0.59) | GAAHTTLMNAMAPTNPC1 | |
| SCHEMBL18458382 | 0.79 | PDK1 (0.68) | GAAHTTLMNAMAPTNPC1 | |
| SCHEMBL6351755 | 0.79 | PDK1 (0.71) | GAAHTTLMNAMAPTPDK1 | |
| SCHEMBL7299817 | 0.78 | GAA (0.56) | GAAHTTLMNAMAPTNPC1 | |
| SCHEMBL30797039 | 0.77 | PDK1 (0.50) | HTTLMNANPC1KMT2AMEN1 | |
| SCHEMBL4675699 | 0.77 | PDK1 (0.50) | HTTLMNANPC1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240391922-A1 | PYRROLOPYRROLE COMPOSITIONS AS PYRUVATE KINASE (PKR) ACTIVATORS | Novo Nordisk Heathcare AG (CH) | 2024-11-28 | — | — | US | disclosed |
| US-12071440-B2 | Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators | NOVO NORDISK HEALTH CARE AG (CH) | 2024-08-27 | — | — | US | disclosed |
| US-20240083901-A1 | PYRROLOPYRROLE COMPOSITIONS AS PYRUVATE KINASE (PKR) ACTIVATORS | NOVO NORDISK HEALTH CARE AG (CH) | 2024-03-14 | — | — | US | disclosed |
| US-11649242-B2 | Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators | FORMA THERAPEUTICS, INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-11649242-B2 | Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators | FORMA THERAPEUTICS, INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-11649242-B2 | Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators | FORMA THERAPEUTICS, INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-RE49080-E1 | Glycoside derivatives and uses thereof | NOVARTIS AG (CH) | 2022-05-24 | — | — | US | disclosed |
| CN-113456634-A | Pyrrolopyrrole compositions as Pyruvate Kinase (PKR) activators | 福马治疗股份有限公司 | 2021-10-01 | — | — | CN | disclosed |
| US-20210246143-A1 | PYRROLOPYRROLE COMPOSITIONS AS PYRUVATE KINASE (PKR) ACTIVATORS | NOVO NORDISK HEALTH CARE AG, (CH) | 2021-08-12 | — | — | US | disclosed |
| CN-109311897-B | Pyrrolopyrrole compositions as Pyruvate Kinase (PKR) activators | 福马治疗股份有限公司 | 2021-07-20 | — | — | CN | disclosed |
| US-20110171159-A1 | Glycoside Derivatives and Uses Thereof | NOVARTIS AG (CH) | 2011-07-14 | — | — | US | disclosed |
| WO-2011048148-A2 | GLYCOSIDE DERIVATIVE AND USES THEREOF | NOVARTIS AG (CH) | 2011-04-28 | — | — | WO | disclosed |
| WO-2011048112-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2011-04-28 | — | — | WO | disclosed |
| EP-1750704-B1 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL MYERS SQUIBB CO (US) | 2009-07-22 | — | — | EP | disclosed |
| US-7550499-B2 | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-23 | — | — | US | disclosed |
| EP-1985297-A1 | CARBOXYLIC ACID COMPOUND AND USE THEREOF | Japan Tobacco, Inc. (JP) | 2008-10-29 | — | — | EP | disclosed |
| US-20070197512-A1 | Carboxylic Acid Compounds and Use Thereof | JAPAN TOBACCO INC. (JP) | 2007-08-23 | — | — | US | disclosed |
| EP-1750704-A2 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | Bristol-Myers Squibb Company (US) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005113537-A2 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-12-01 | — | — | WO | disclosed |
| US-20050261244-A1 | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL-MYERS SQUIBB COMPANY | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240391922-A1 | PYRROLOPYRROLE COMPOSITIONS AS PYRUVATE KINASE (PKR) ACTIVATORS | PDK1, PKM, PKLR | GAA 651/4885HTT 1043/4885LMNA 2219/4885 |
| US-12071440-B2 | Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators | PDK1, PKM, PKLR | GAA 651/4885HTT 1043/4885LMNA 2219/4885 |
| US-20240083901-A1 | PYRROLOPYRROLE COMPOSITIONS AS PYRUVATE KINASE (PKR) ACTIVATORS | PDK1, PKM, PKLR | GAA 651/4885HTT 1043/4885LMNA 2219/4885 |
| US-20210246143-A1 | PYRROLOPYRROLE COMPOSITIONS AS PYRUVATE KINASE (PKR) ACTIVATORS | PDK1, PKM, PKLR | GAA 651/4885HTT 1043/4885LMNA 2219/4885 |
| US-20110171159-A1 | Glycoside Derivatives and Uses Thereof | SLC5A1, SLC5A2, SLC2A1 | GAA 145/4885HTT 1370/4885LMNA 3972/4885 |
| US-20070197512-A1 | Carboxylic Acid Compounds and Use Thereof | GLS, SLC10A1, SOAT1 | GAA 783/4885HTT 772/4885LMNA 4136/4885 |
| US-20050261244-A1 | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | P2RY1, P2RY11, P2RY2 | GAA 2434/4885HTT 1607/4885LMNA 3730/4885 |
| US-11649242-B2 | Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators | PDK1, PKM, PKLR | GAA 651/4885HTT 1043/4885LMNA 2219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.